BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Expectations Audits

Visa’s Price Assumes the Party Ends. The Filings Say It Hasn’t.

Moe Alsumidaie by Moe Alsumidaie
October 23, 2026
in Expectations Audits
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Payments volume crossed $4 trillion in a single quarter for the first time in Visa’s history this past July. Four weeks later, the stock was sitting at an all-time high. Those two facts sound like they belong together, until you notice that the price-to-earnings multiple Visa carries today sits at the 89th percentile of its own decade, meaning the stock has been cheaper than this nine years out of ten. A business breaking records and a valuation priced for perfection are not the same story.

Before anything else

The filed numbers show a business that has grown revenue every year since the pandemic trough, expanded net margins past 50%, and just reported its strongest quarterly top-line growth in years. The stock, at $414, is priced at a multiple that our data places in the top 11% of Visa’s own history, implying the market expects that pace to continue without interruption. The open question is whether the headwinds management flagged, rising client incentives, currency drag, and antitrust pressure, are large enough to close that gap, or whether the price is simply demanding more than the math can deliver.

How Visa became a toll road

Visa does not lend money. It does not hold deposits. It runs the pipes that connect a merchant’s card terminal to a cardholder’s bank, and it collects a small fee on every transaction that flows through. Think of it as a toll road: the company does not care whether the car is a Ford or a Ferrari, only that it uses the road. That model produces margins most manufacturers can only dream about, and it has proved remarkably durable across recessions, pandemics, and regulatory fights.

The pandemic was the sharpest test. Cross-border travel collapsed in 2020, and with it the international transaction fees that carry Visa’s fattest margins. The recovery was not instant, but by fiscal 2023 revenue had climbed to $32.7 billion, and by fiscal 2025 it reached $40 billion, with net margins holding above 50% the entire way. That is the backstory: a business that bent but did not break, growing at roughly 10% a year ever since the world reopened.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Visa and 500+ other names, on the same official data.See the evidence engine →

A business growing at that pace doubles in size roughly every seven years without heavy borrowing or capital expenditure, a profile that has historically commanded a valuation premium in public markets.

What the most recent quarter actually shows

The most recent filed period is fiscal Q3 2026, ended June 30, 2026. Revenue came in at $11.6 billion for the quarter, up 14% from a year earlier, and the operating margin was 59%, meaning nearly six of every ten dollars of revenue flowed through to operating profit before taxes. That is not a business in distress.

Cross-border volume, the high-margin international spending that collapsed during COVID, grew strongly in constant dollars. Travel volumes and cross-border e-commerce both expanded at a healthy clip, partly helped by the FIFA World Cup drawing international card spending. Value-added services, a newer revenue line covering fraud tools, data analytics, and consulting sold on top of the core network, grew at more than twice the headline rate and now represent a meaningful share of total revenue. Visa Direct, the real-time money-movement product that competes with wire transfers and bank ACH rails, processed billions of transactions in the quarter, up more than a fifth year-over-year.

Q4 2026 results are due October 27, 2026, four days from today. The full-year picture will sharpen then, but the trajectory through June is clear: the business is accelerating, not slowing.

The line items that complicate the picture

Here is where the audit gets interesting. Client incentives, the rebates and volume bonuses Visa pays to banks and merchants to keep their cards on the network, came in at $4.7 billion for the quarter, growing faster than revenue. Management told investors the jump partly reflects an unusually low comparison period a year ago, and that the next quarter’s incentive growth would run slightly above this pace as new contracts kick in.

BullScope TerminalYou just read Visa’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

A useful way to hold that number: incentives are the price Visa pays to keep traffic on its toll road. When a big bank renegotiates its contract, Visa often agrees to rebate more per transaction in exchange for volume commitments. That is rational, but it means the headline revenue growth rate flatters the underlying economics slightly. The toll road is busier than ever; the toll keeper is also giving more discounts.

Management also flagged currency headwinds and slower growth in international transaction revenue relative to raw cross-border volume. On the July 28 earnings call, the full-year 2026 outlook called for net revenue growth at the low end of low-teens, with earnings-per-share growth at the low end of mid-teens, both on a non-GAAP constant-dollar basis. Trefis, writing on October 22, noted that international transaction revenue grew well behind the headline rate in Q3, calling it “falling behind” other revenue streams.

A business can show strong top-line growth while quietly giving more of it away in discounts and absorbing currency losses. The filed numbers do not hide this, but the headline figure does not shout it either.

The math versus the mood

“The math” is what the filed fundamentals justify; “the mood” is what the market is currently paying. At $414, our data puts Visa’s price-to-earnings multiple at the 89th percentile of its own decade. The price-to-sales ratio sits at the same percentile. The mood, in other words, is generous.

Analyst consensus estimates compiled as of this week, per valueinvesting.io, project fiscal 2026 revenue near $46 billion and meaningful earnings-per-share growth beyond that. Zacks Equity Research on October 22 put Visa’s forward price-to-earnings ratio at roughly twice the industry average. GuruFocus, also on October 22, called the stock “fairly valued” at just under $410.

BullScope TerminalVisa was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

The tension is not that the business looks bad. It does not. The tension is that the current price leaves almost no room for the headwinds management already named: incentive cost creep, currency drag, the new lower interchange rates for small merchants effective this month, and a new domestic transaction fee arriving in April 2027. A new class-action lawsuit filed in early October alleging continued inflated swipe fees adds to the antitrust noise that has followed Visa for a decade.

If earnings land at the filed-trend pace and the multiple compresses even modestly toward Visa’s own decade median, the math produces a price meaningfully below today’s. If growth accelerates and the multiple holds, the mood wins. The filed numbers cannot tell us which happens, and we will not pretend otherwise.

The new bets worth watching

Visa’s acquisition of BioCatch, a behavioral biometrics firm, closed in August 2026 for roughly two and a half billion dollars. Visa also announced a risk-sharing initiative with the International Finance Corporation to expand digital payments in emerging markets. Partnerships with Goldman Sachs, Airbnb, ADP, and PayPal were announced in early October. And the company is redirecting severance savings toward AI and product development, a signal that management sees the next margin lever in software, not headcount.

Analysts at Public.com flagged on October 21 that government-backed payment rails like India’s UPI and Brazil’s Pix represent a genuine long-run threat to Visa’s toll-road model in fast-growing markets. MarketBeat on October 15 countered that Visa’s stablecoin-enabled Visa Direct prefunding service “strengthens Visa’s position in digital-asset payments.” Both can be true: the core network faces pressure at the edges while the company builds new revenue lines in the middle.

The open analytical question is whether those new bets are already priced in at a multiple nearly twice the industry average, or whether they represent upside the market has not yet credited.

Reading the numbers

  • $11.6 billion, Q3 2026 operating revenue, up 14% year-over-year. What it is: the money Visa collected from banks and merchants for use of its network in a single quarter. What it means here: the growth rate is the fastest in several years, suggesting the business is not decelerating. Everyday example: a family that earned $100,000 last year and $114,000 this year, with no new job, just more hours on the same road.
  • 59% operating margin, Q3 2026. What it is: the share of each revenue dollar left after paying employees, technology, and overhead, before taxes. What it means here: nearly six of every ten dollars Visa collects becomes operating profit. Everyday example: a landlord who collects $1,000 in rent and spends $410 on maintenance, insurance, and management, keeping $590.
  • $4.7 billion in client incentives, Q3 2026, up 18%. What it is: rebates and volume bonuses paid back to banks and merchants. What it means here: incentives are growing faster than revenue, which compresses the net revenue Visa actually retains. Everyday example: a store offering a loyalty discount that costs more each year to maintain as the customer base grows.
  • P/E at the 89th percentile of Visa’s own decade, per our data. What it is: the price-to-earnings multiple (the price tag per dollar of annual profit) ranked against Visa’s own history. What it means here: the stock has been cheaper than this nine years out of ten. Everyday example: paying $890,000 for a house in a neighborhood where the same house has sold for between $500,000 and $1 million over the past decade, and usually closer to $700,000.
  • 12% cross-border volume growth, constant dollars, Q3 2026. What it is: the pace at which international card spending on Visa’s network expanded, stripped of currency effects. What it means here: the high-margin international business that collapsed in 2020 is still recovering strongly, which is the primary engine of margin expansion. Everyday example: a toll road that handles 12% more cross-state trucks than a year ago, with each truck paying a higher fee than local traffic.

Sources

  • Visa Q3 2026 Earnings Release (filed July 28, 2026)
  • Visa 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
  • Visa 10-K, fiscal year ended September 30, 2025 (SEC EDGAR)
  • Visa 10-K, fiscal year ended September 30, 2024 (SEC EDGAR)
  • Visa 10-K, fiscal year ended September 30, 2023 (SEC EDGAR)
  • Visa Q4 2026 earnings announcement date (investor.visa.com)
  • Visa Q3 2026 earnings call transcript (Investing.com)
  • Visa Q3 FY2026 slides: payments volume tops $4T (Investing.com)
  • Visa Q3 earnings: $4 trillion volume and layoffs (TIKR)
  • Zacks Equity Research on Visa valuation, October 22, 2026
  • Trefis on Visa international transaction revenue, October 22, 2026
  • Analyst consensus estimates for Visa FY2026 and FY2027 (valueinvesting.io)
  • Visa and IFC risk-sharing initiative announcement
  • Visa Q3 2026 earnings summary (Tickeron)
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Visa’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Vertex Pharmaceuticals: Three Things the Street Is Saying, and What the Filings Actually Show

by Moe Alsumidaie
October 21, 2026
0

Vertex spent most of the last decade as a one-disease company that happened to be extraordinarily good at that disease. Cystic fibrosis is rare, the science is brutal,...

Read moreDetails

Alphabet’s Margins Are the Best They’ve Ever Been. The Stock Assumes They Stay That Way Forever.

by Moe Alsumidaie
October 16, 2026
0

A 34% operating margin and a share price sitting meaningfully below its peak: those two facts should not coexist in a simple story. Either the margin is under...

Read moreDetails

Merck’s Split Screen: Margins at a Decade High, a Stock Priced for Catastrophe

by Moe Alsumidaie
October 14, 2026
0

Two numbers sit side by side and refuse to make sense together. The 10-K filed in February 2026 shows Merck & Co, the US company that trades as...

Read moreDetails

Mirum Pharmaceuticals: A Pipeline on Fire, a Price That Went Cold

by Moe Alsumidaie
October 12, 2026
0

Three Phase 3 trials hit their primary endpoints in the span of two weeks. The stock is sitting roughly a third below its 52-week high. Those two facts...

Read moreDetails

Costco at $948: The Filed Numbers vs. What the Price Tag Demands

by Moe Alsumidaie
October 9, 2026
0

A stock sitting well below its 52-week high while posting the best operating margin in at least seven years. Those two facts should not coexist, and the gap...

Read moreDetails
Next Post

Arcutis: One Drug, Shrinking Losses, and a Label That Keeps Growing

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Evidence Sheet: Deere & (DE)

August 31, 2026

Evidence Sheet: Regeneron Pharmaceuticals (REGN)

October 7, 2026

Honeywell Broke Itself in Three. The Price Hasn’t Decided What to Think Yet.

August 11, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.